# Dose-Finding Study To Evaluate The Efficacy, Tolerability And Safety Of Fesoterodine In Comparison To Placebo For Overactive Bladder.

> **NCT00561951** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 951 (actual)

## Conditions studied

- Overactive Bladder

## Interventions

- **DRUG:** fesoterodine fumarate
- **DRUG:** Placebo
- **DRUG:** fesoterodine fumarate

## Key facts

- **NCT ID:** NCT00561951
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2009-01
- **Final completion:** 2009-01
- **Target enrollment:** 951 (ACTUAL)
- **Last updated:** 2011-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00561951

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00561951, "Dose-Finding Study To Evaluate The Efficacy, Tolerability And Safety Of Fesoterodine In Comparison To Placebo For Overactive Bladder.". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT00561951. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*